Brian Marckx, CFA
Long/short equity

Revenue Hit From Loss Of Manufacturing Customer But Recent Sell-Off Overdone

BioLife Solutions (NASDAQ:BLFS) announced results for Q1 2014. Revenue of $2.1M was about 4% lower yoy although excluding $609k in non-recurring licensing revenue booked in Q1 2013, total revenue growth was 33%. Even more importantly growth in product revenue, which will be the long-term driver of the top-line (as opposed to contract manufacturing revenue), increased by 47% from the $770k booked in Q1 2013. Product revenue of $1.13M was just shy of the $1.21M record set in Q4 2013 and marks the third straight quarter above $1M. Management reiterated product sales growth guidance of 25% - 35% for the full year.

Meanwhile, contract manufacturing grew 20% to $933k. Unfortunately contract manufacturing revenue, which has buoyed the top-line over

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details